Calcitonin use in giant cell bone tumors - 31/08/11
, M. Hedi Meherzi, M. Ouertatani, M. Mestiri, K. Zehi, M. Douik, M. Zouari
Corresponding author.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Summary |
Introduction |
As osteoclast, giant cell tumors express calcitonin receptors. The aim of this paper is to assess treatment using salmon calcitonin after curettage.
Material and methods |
We retrospectively reviewed 25 patients with giant cell tumor of the appendicular skeleton treated with a single protocol of calcitonin administration following curettage in order to assess the effectiveness of calcitonin in reducing the rate of local recurrence.
Results |
The mean duration follow-up was 68 months. Thirteen patients (52%) had local recurrence. Eight of them were treated successfully after repeated curettage and calcitonin. Four patients had bone resection and one patient had curettage and cement filling. All patients with cavity left empty had ossified and the functional score as assessed by the MSTS score was 28.02/30.
Conclusion |
This study suggests that the use of calcitonin as adjuvant is not effective and that filling agents are not required after curettage of giant cell tumors.
Level of evidence |
Level 4.
Le texte complet de cet article est disponible en PDF.Keywords : Giant cell tumor, Calcitonin, Bone
Plan
Vol 97 - N° 5
P. 520-526 - septembre 2011 Retour au numéro
Article précédent
- Intercalary defects reconstruction of the femur and tibia after primary malignant bone tumour resection. A series of 13 cases
- O. Brunet, P. Anract, S. Bouabid, A. Babinet, V. Dumaine, B. Toméno, D. Biau
- Percutaneous management of thoracolumbar burst fractures: Evolution of techniques and strategy
- B. Blondel, S. Fuentes, G. Pech-Gourg, T. Adetchessi, P. Tropiano, H. Dufour
Bienvenue sur EM-consulte, la référence des professionnels de santé.